EA201600002A1 - Производные пролекарства замещенных триазолопиридинов - Google Patents

Производные пролекарства замещенных триазолопиридинов

Info

Publication number
EA201600002A1
EA201600002A1 EA201600002A EA201600002A EA201600002A1 EA 201600002 A1 EA201600002 A1 EA 201600002A1 EA 201600002 A EA201600002 A EA 201600002A EA 201600002 A EA201600002 A EA 201600002A EA 201600002 A1 EA201600002 A1 EA 201600002A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
triazolopiridines
substituted
mps
diseases
Prior art date
Application number
EA201600002A
Other languages
English (en)
Inventor
Фолькер Шульце
Ханс-Георг Лерхен
Дональд Бирер
Антье Маргрет Венгнер
Герхард Зимайстер
Филип Линау
Урзула Кренц
Дирк Коземунд
Детлеф Штёкигт
Михаель Брюнинг
Ульрих Люкинг
Ильдико Теребези
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201600002A1 publication Critical patent/EA201600002A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Настоящее изобретение относится к производным пролекарств ингибиторов Mps-1 киназы формулы (I), к способам их получения, а также к их применению для лечения и/или профилактики заболеваний.
EA201600002A 2013-06-11 2014-06-06 Производные пролекарства замещенных триазолопиридинов EA201600002A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171508 2013-06-11
PCT/EP2014/061779 WO2014198647A2 (en) 2013-06-11 2014-06-06 Prodrug derivatives of substituted triazolopyridines

Publications (1)

Publication Number Publication Date
EA201600002A1 true EA201600002A1 (ru) 2016-06-30

Family

ID=48576905

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600002A EA201600002A1 (ru) 2013-06-11 2014-06-06 Производные пролекарства замещенных триазолопиридинов

Country Status (35)

Country Link
US (1) US9586958B2 (ru)
EP (1) EP3008062B1 (ru)
JP (1) JP2016526534A (ru)
KR (1) KR20160019492A (ru)
CN (1) CN105377848A (ru)
AP (1) AP2015008898A0 (ru)
AR (1) AR096585A1 (ru)
AU (1) AU2014280356A1 (ru)
CA (1) CA2914745A1 (ru)
CL (1) CL2015003605A1 (ru)
CR (1) CR20150659A (ru)
CU (1) CU20150176A7 (ru)
DK (1) DK3008062T3 (ru)
DO (1) DOP2015000299A (ru)
EA (1) EA201600002A1 (ru)
ES (1) ES2626790T3 (ru)
HK (1) HK1221955A1 (ru)
HR (1) HRP20170717T1 (ru)
HU (1) HUE033131T2 (ru)
IL (1) IL242847A0 (ru)
LT (1) LT3008062T (ru)
MA (1) MA38654B1 (ru)
MX (1) MX2015017119A (ru)
NI (1) NI201500176A (ru)
PE (1) PE20160156A1 (ru)
PH (1) PH12015502746A1 (ru)
PL (1) PL3008062T3 (ru)
PT (1) PT3008062T (ru)
RS (1) RS56034B1 (ru)
SG (1) SG11201509858QA (ru)
SI (1) SI3008062T1 (ru)
TN (1) TN2015000545A1 (ru)
UY (1) UY35610A (ru)
WO (1) WO2014198647A2 (ru)
ZA (1) ZA201508868B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
CN109310686B (zh) 2016-04-04 2022-06-21 凯莫森特里克斯股份有限公司 可溶性C5aR拮抗剂
WO2023113478A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Methods of treating neoplastic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE340176T1 (de) 1996-08-28 2006-10-15 Pfizer Substituierte 6,5-heterobicyclische-derivate
EP0991628B1 (en) 1997-05-28 2005-01-12 Aventis Pharmaceuticals Inc QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2004346016A (ja) 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
JP2008515874A (ja) 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
EA200870592A1 (ru) 2006-05-31 2009-08-28 Галапагос Н.В. Триазолопиразиновые соединения, пригодные для лечения дегенеративных и воспалительных заболеваний
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
US7592342B2 (en) 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
MX2010000716A (es) 2007-07-18 2010-03-26 Novartis Ag Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
EP2173354A4 (en) 2007-08-09 2011-10-05 Glaxosmithkline Llc CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
NZ584138A (en) 2007-08-23 2011-10-28 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010005700A (es) 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
NZ594508A (en) 2009-02-13 2013-12-20 Fovea Pharmaceuticals [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2473498A1 (en) 2009-09-04 2012-07-11 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
EA023766B1 (ru) 2011-04-21 2016-07-29 Байер Интеллектчуал Проперти Гмбх Триазолопиридины
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
EP2825540B1 (en) 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
PE20150354A1 (es) * 2012-07-10 2015-03-21 Bayer Pharma AG Metodos para preparar triazolopiridinas sustituidas
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
CN105431435A (zh) * 2013-06-07 2016-03-23 拜耳制药股份公司 具有作为mps-1抑制剂的活性的取代的***并吡啶类
CA2914668A1 (en) * 2013-06-10 2014-12-18 Volker Schulze Novel compounds for the treatment of cancer
EP3007692A1 (en) * 2013-06-11 2016-04-20 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor

Also Published As

Publication number Publication date
MA38654B1 (fr) 2018-11-30
CR20150659A (es) 2016-01-29
PT3008062T (pt) 2017-06-07
US9586958B2 (en) 2017-03-07
AR096585A1 (es) 2016-01-20
US20160207915A1 (en) 2016-07-21
AP2015008898A0 (en) 2015-12-31
JP2016526534A (ja) 2016-09-05
KR20160019492A (ko) 2016-02-19
CN105377848A (zh) 2016-03-02
PL3008062T3 (pl) 2017-08-31
ES2626790T3 (es) 2017-07-26
HK1221955A1 (zh) 2017-06-16
CU20150176A7 (es) 2016-05-30
DK3008062T3 (en) 2017-06-12
WO2014198647A2 (en) 2014-12-18
MX2015017119A (es) 2016-04-06
SG11201509858QA (en) 2015-12-30
AU2014280356A1 (en) 2015-12-24
HUE033131T2 (en) 2017-11-28
TN2015000545A1 (en) 2017-04-06
WO2014198647A3 (en) 2015-02-05
CA2914745A1 (en) 2014-12-18
LT3008062T (lt) 2017-06-12
NI201500176A (es) 2016-01-06
EP3008062B1 (en) 2017-04-05
EP3008062A2 (en) 2016-04-20
RS56034B1 (sr) 2017-09-29
UY35610A (es) 2015-01-30
DOP2015000299A (es) 2016-03-15
CL2015003605A1 (es) 2016-06-24
IL242847A0 (en) 2016-02-01
PH12015502746A1 (en) 2016-03-21
HRP20170717T1 (hr) 2017-07-28
ZA201508868B (en) 2017-08-30
PE20160156A1 (es) 2016-04-20
SI3008062T1 (sl) 2017-06-30

Similar Documents

Publication Publication Date Title
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201690752A1 (ru) Ингибиторы g12c kras
EA201691354A1 (ru) Терапевтические ингибирующие соединения
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201690844A1 (ru) Ингибиторы gsk-3
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
EA201691141A1 (ru) Соединения против ccr6
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)